BPH: Epidemiology and Comorbidities

The document reviewed the epidemiology and comorbidities associated with benign prostatic hyperplasia (BPH). It was noted that BPH, characterized by moderate-to-severe lower urinary tract symptoms (LUTS), affected about 25% of men in their 50s, 33% in their 60s, and 50% of men aged 80 and older. Despite the availability of effective treatments, BPH often co-occurred with age-related conditions such as cardiovascular disease, hypertension, and erectile dysfunction. The primary treatments included alpha1-selective adrenergic receptor antagonists and 5-alpha-reductase inhibitors, which were particularly effective in men with larger prostates when used in combination. The review emphasized the importance of considering side effects and their impact on existing comorbidities when selecting a treatment plan.